- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02213952
PRP ULCERAS: Clinical Trial Phase III (PRPULCERAS)
Efficacy of Autologous Platelet-Rich Plasma in the Treatment of Vascular Ulcers in Primary Care: Clinical Trial Phase III
INTRODUCTION: Vascular ulcers are an important pathology in the daily medical practice in all the assistance levels, and they have big repercussion referring to individual, social and labour levels, supposing a big consumption of human and material resources.The cure with autologous platelet rich plasma (autologous PRP) has demonstrated in different studies a decrease in the cicatrization time comparing to conventional methods in hospital levels, which becomes interesting contrasting its efficacy in primary care.
AIM:Evaluate the efficacy of the autologous PRP in the treatment of vascular ulcers, comparing to the conventional treatment ( cure with humid environment), in primary care patients with chronic venous insufficiency in C-6 degree (CEAP classification).
DESIGN: A study will be executed, which will consist in a randomized clinical test, multicentered, in parallel groups and opened. 150 patients suffering of venous vascular ulcers will be studied, who will be between the age of 40-100 years old, and who will be attached to 10 health centers. Variables for the identification, following, result and patient profile have been defined. Emphasize the variables of "ulcer area decreasing", "CIVIQ index", "% one cure per week".
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Bizakaia
-
Portugalete, Bizakaia, Spain, 48920
- Comarca Enkarterri Ezkerraldea
-
-
Bizkaia
-
Bilbao, Bizkaia, Spain, 48014
- UIAPB
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients from Barakaldo and Bilbao, who come to the treatment room at health centers in these towns belong to the OSI Ezkerraldea-Enkarterri-Cruces of Osakidetza-Basque Health Service.
- Men or women older than 18 years old.
- Patients with chronic venous insufficiency stage C-6 of the CEAP classification.
- Patients with vascular ulcers unresponsive to conventional treatment over a 2 months period or recurrence of previous venous ulcers.
- Patients who present an analytical before entering the studio, platelets and red blood cell count and hematocrit in normal range
- Ulcers whose diameter size is 30cm² or less.
- Greater Ankle Arm Index 0.8 and less than 1.5.
- Patients with recent analytic with number platelet and red blood cell count and hematocrit normal range.
- Patients with recent analytic negative to: Syphilis serology, Hepatitis B: HBsAg, Hepatitis C: Anti-HCV tests genomic nucleic acid amplification (NAT), HIV I / II: Anti-HIV I / II.
- Self or family support sufficient to move patients to the health center.
- Written informed consent of the patient
Exclusion Criteria:
- Patients on chronic immunosuppressive or retroviral.
- Coagulopathy
- Patients with chronic infectious diseases.
- Patients treated with radiotherapy or chemotherapy, or history of neoplasia.
- Patients with more than two active ulcers.
- Pregnant or childbearing potential not want to use contraception.
- Women breastfeeding.
- Patients with active infection or febrile syndrome at baseline.
- People who are taking a drug under clinical investigation or participated in any study under clinical investigation in the previous 30 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Platelet-Rich Plasma
Our goal is to evaluate the efficacy of the autologous Platelet-Rich Plasma (PRP) in the treatment of vascular ulcers, comparing to the conventional treatment (cure with humid environment), in primary care patients with chronic venous ulcer.
|
For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate.
The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient.
After centrifugation, we will aspire the PRP.
We will add CaCl2 to the PRP (50l per ml of liquid plasma).
While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal.
Then the ulcer will be covered with gelified PRP and a secondary dressing.
This cure will be done each 7 days.
Other Names:
|
Active Comparator: Usual treatment
Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure.
The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection.
These cures will be performed every 48-72 hours.
|
Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure.
The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection.
These cures will be performed every 48-72 hours.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ULCER SIZE CHANGE
Time Frame: Change from baseline at 9 weeks
|
Change from baseline at 9 weeks of the surface area of the ulcer, in cm2, measured using ImageJ software from the weekly the photographs of the wound.
|
Change from baseline at 9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QUALITY OF LIFE (INDEX CIVIQ)
Time Frame: Change from baseline at 9 weeks
|
Change of the CIVIQ SCORE.
20-item self-reported quality of life questionnaire scale called Chronic Venous disease quality of life Questionnaire-20 (CIVIQ-20) was created and validated in France in 1996,1 as a sensitive instrument to capture the key dimensions of quality of life (QoL) specifically impaired by chronic venous disease (CVD).
Four dimensions of the CIVIQ-20 were identified: physical (4 items), psychological (9 items), social (3 items), and pain (4 items).
|
Change from baseline at 9 weeks
|
Change of the percentage OF PATIENTS WITH A ONLY ONE TREATMENT FOR WEEK
Time Frame: Change from baseline at 9 weeks
|
Change of the percentage OF PATIENTS WITH A ONLY ONE TREATMENT FOR WEEK
|
Change from baseline at 9 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kepa Mirena San Sebastian Moreno, C. Ezkerraldea Enkarterri.
- Study Chair: Igone Hernández Cabezas., C. Ezkerraldea Enkarterri
- Study Chair: Igone Lobato García, C. Ezkerraldea Enkarterri
- Study Chair: Begoña Rodríguez Rodríguez., C. Bilbao
- Study Chair: Ariadna Pérez Salvador, C. Ezkerraldea Enkarterri
- Study Chair: Gonzalo Grandes Odriozola, Primary care research unit of Bizkaia
- Study Director: Natalia Burgos Alonso., Primary care research unit of Bizkaia
- Study Director: Anna Giné March, Primary care research unit of Bizkaia
- Principal Investigator: Kepa Mirena San Sebastian Moreno, C. Ezkerraldea Enkarterri
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UIAPB-PRPULCERAS-2014-02
- 2014-001514-26 (Other Grant/Funding Number: UIAPB-PRPULCERAS-2014)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcer
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownBleeding Gastric Ulcer | Bleeding Duodenal UlcerChina
-
Groupe Hospitalier Paris Saint JosephCompletedUlcer, Leg | Ulcer AlgicFrance
-
Paul EdwardsCompletedDecubitis UlcerUnited States
-
King Chulalongkorn Memorial HospitalCompletedGastric Ulcer Induced by Anti-platelet Agent | Duodenal Ulcer Induced by Anti-platelet AgentThailand
-
AstraZenecaCompletedGastric Ulcer | Duodenal UlcerUnited States, Bulgaria, Czech Republic, Korea, Republic of, Russian Federation, South Africa, Philippines, Poland, Romania, Finland, Norway, Canada, Mexico, Argentina, Australia, Germany, Portugal, Slovakia, Thailand, Indonesia
-
Assistance Publique - Hôpitaux de ParisRecruitingVenous Ulcer | Diabetic Ulcer | Sickle Cell Ulcer | Post-partum Women | Mixed UlcerFrance
-
Smith & Nephew, Inc.TerminatedSurgical Incision | Pressure Ulcer | Ulcer Foot | Wound Dehiscence | Ulcer, Leg | Ulcer VenousUnited Kingdom, Germany
-
Zagazig UniversityCompletedUlcer Foot | Chronic Skin Ulcer | Non-Healing Ulcer of SkinEgypt
-
The Catholic University of KoreaSt Vincent's Hospital; Bucheon St. Mary's HospitalUnknown
-
Taipei Veterans General Hospital, TaiwanUnknownGastric Ulcer | Duodenal UlcerTaiwan
Clinical Trials on Platelet-Rich Plasma
-
Stanford UniversityPartnership for Clean CompetitionCompletedRheumatic Diseases | TendinopathyUnited States
-
VivaTech International, Inc.RecruitingOsteoarthritisUnited States
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingMenopause, Premature | Menopausal Syndrome | Premature Ovarian Failure | Ovarian Failure, Premature | Menopause Related ConditionsGreece
-
Cardenal Herrera UniversityCompletedCarpal Tunnel SyndromeSpain
-
Rajavithi HospitalRecruitingAutologous Platelet-rich Plasma Supplement | Sperm Cryopreservation | Post-cryopreserved Sperm Quality | Semen AnalysisThailand
-
Damascus UniversityCompletedBone ResorptionSyrian Arab Republic
-
Peking University Third HospitalRecruiting
-
Matthew GettmanCompleted
-
Sutherland Medical CenterActive, not recruitingRotator Cuff Tears | Rotator Cuff TendinosisPoland
-
EgymedicalpediaAl-Azhar UniversityCompletedUrinary Incontinence | Stress Urinary IncontinenceEgypt